Rational approaches to design of therapeutics targeting molecular markers.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn , Issue , 2001, Pages 443-462

  Klasa, R J ^a   List, A F ^a   Cheson, B D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CYCLIN D1; CYSTEINE PROTEINASE; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; MULTIENZYME COMPLEX; PROTEASOME; PROTEIN BCL 2; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL; BLOOD DISEASE; CELL CYCLE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; HUMAN; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CYCLIN D1; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; ENDOTHELIAL GROWTH FACTORS; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOKINES; MULTIENZYME COMPLEXES; OLIGONUCLEOTIDES, ANTISENSE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035225605     PISSN: 15204391     EISSN: None     Source Type: Journal    
DOI: 10.1182/asheducation-2001.1.443     Document Type: Review

References (53)